Literature DB >> 2365984

Flutamide-induced liver failure.

S Møller1, P Iversen, M B Franzmann.   

Abstract

Two cases of clinically manifest liver failure in patients with metastatic prostatic cancer treated with the non-steroidal antiandrogen flutamide combined with a luteinizing hormone-releasing hormone analogue are described. One patient developed severe hepatic insufficiency with jaundice, ascites and hepatic coma. The condition reversed after discontinuation of flutamide. The other patient only became jaundiced with a biochemical cholestatic pattern. Previous reports of hepatic adverse reactions only include elevated transaminase levels without clinical manifestations. The morphological lesions in the liver biopsy and the clinical condition may be due to a reversible interaction with metabolic processes in the hepatocytes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2365984     DOI: 10.1016/0168-8278(90)90144-g

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  9 in total

Review 1.  Dose adaptation of antineoplastic drugs in patients with liver disease.

Authors:  Lydia Tchambaz; Chantal Schlatter; Max Jakob; Anita Krähenbühl; Peter Wolf; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism.

Authors:  M Pirmohamed; S Madden; B K Park
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

3.  Clinical efficacy of lower dose flutamide 125 mg/day in the treatment of hirsutism.

Authors:  I I Müderris; F Bayram
Journal:  J Endocrinol Invest       Date:  1999-03       Impact factor: 4.256

4.  Cholestatic hepatitis following flutamide.

Authors:  A S Rosman; C Frissora-Rodeo; A T Marshall; B P Reiter; F Paronetto
Journal:  Dig Dis Sci       Date:  1993-09       Impact factor: 3.199

5.  Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis.

Authors:  C Cicognani; M Malavolti; A M Morselli-Labate; C Sama; L Barbara
Journal:  Dig Dis Sci       Date:  1996-11       Impact factor: 3.199

6.  3D, large-area NiCo2O4 microflowers as a highly stable substrate for rapid and trace level detection of flutamide in biofluids via surface-enhanced Raman scattering (SERS).

Authors:  Lignesh Durai; Sushmee Badhulika
Journal:  Mikrochim Acta       Date:  2021-10-08       Impact factor: 5.833

Review 7.  Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer.

Authors:  R N Brogden; P Chrisp
Journal:  Drugs Aging       Date:  1991-03       Impact factor: 3.923

Review 8.  [Toxic hepatitis and liver failure under therapy with flutamide].

Authors:  C Lübbert; M Wiese; R Haupt; B R Ruf
Journal:  Internist (Berl)       Date:  2004-03       Impact factor: 0.743

9.  Microscopic polyangiitis complicated by the development of prostate cancer and flutamide-induced hepatitis.

Authors:  D Papaioannides; P Korantzopoulos; C Bouropoulos; P Latsi; M Fotinou; D Orphanidou
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.266

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.